Pipeline

Advancing Novel Therapeutics to Elevate the Standard of Care

Development Programs

AngioGenex is committed to the discovery and advancement of new medicines that have the potential to relieve suffering and improve quality of life for patients in need.

 Discovery

  Preclinical

Phase 1

AGX-A

Cholangiocarcinoma

Preclinical

40%

AGX-A

Age-related macular degeneration (AMD)

Discovery

20%

AGX-A is a Novel Id Protein Inhibitor

AGX-A is a small molecule therapeutic that has been rationally designed and targeted against certain cancers and age-related macular degeneration. AGX-A works by inhibiting the activity of Id proteins.

AGX-A Selectively Binds to Id Proteins Targeting Them for Degradation

AngioGenex researchers analyzed the 3D structure of Id and identified a “crevice” between the a-helices (green) suitable for drugging.

Id Protein

Cholangiocarcinoma is a Cancer that Forms in Bile Ducts

Cholangiocarcinoma is cancer of the bile ducts. Bile ducts the digestive fluid bile and connect your liver to your gallbladder and small intestine. Also known as bile duct cancer, cholangiocarcinoma is very difficult to treat. Fewer than 20,000 cases occur each year in the U.S. and the 5 year survival rate with surgery and standard chemotherapy can be as low as 10%.